TruScreen Group Limited (NZX/ASX: TRU), a cervical cancer screening technology company, reported an operating loss of $1.22m for the half-year ended 30 September 2022.
Despite the challenging market conditions due to the COVID-19 pandemic, the company maintained its revenue base of $0.74m.
Market developments in China, Latin America and Zimbabwe show potential for further growth, while the company has invested heavily in transitioning regulatory systems and processes and making cost reductions.
The appointment of Dr Beata Edling as Chief Executive Officer further strengthens the company's outlook for the year ahead.
See more
